2'-Fucosyllactose Composition for GLS1-Targeted Cell Aging Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current technologies lack effective agents for preventing or ameliorating cell aging, particularly focusing on GLS1 gene expression and endoplasmic reticulum stress, which contribute to senescent cell accumulation and tissue deterioration.

Innovation Solution

A prophylactic or ameliorating agent comprising 2'-fucosyllactose (2'-FL) is used to inhibit GLS1 gene expression, promote normal cell proliferation, and remove senescent cells, thereby addressing cell aging and associated conditions such as wrinkles, sagging, and inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anti-aging agents are used, then some anti-aging effects may be achieved, but they fail to effectively inhibit GLS1 gene expression and remove senescent cells

Engineering Contradiction:

Improveeffectiveness of cell aging preventionVSAvoidability to address multiple aging mechanisms

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies 2'-fucosyllactose as a multi-functional agent that simultaneously addresses multiple aging mechanisms: it inhibits GLS1 gene expression, promotes normal cell proliferation, and removes senescent cells. This single substance performs multiple anti-aging functions that were previously achieved by separate agents, resolving the contradiction between reliability and adaptability.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If GLS1 gene expression is suppressed, then senescent cell accumulation is reduced, but normal cell function may be affected

Engineering Contradiction:

Improvesenescent cell removal efficiencyVSAvoidimpact on normal cell function

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs 2'-fucosyllactose to selectively suppress GLS1 gene expression specifically in senescent cells while leaving normal cells unaffected. This selective action is achieved through the compound's ability to distinguish between senescent and normal cell states, allowing targeted intervention that removes harmful senescent cells without damaging normal cell function.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses 2'-fucosyllactose as an intermediary substance that mediates the suppression of GLS1 gene expression. This intermediary approach allows for controlled inhibition of the gene in senescent cells while maintaining normal cell function, as the compound acts as a bridge between the therapeutic goal and the biological system without causing excessive harm.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If endoplasmic reticulum stress is increased to eliminate senescent cells, then senescent cell removal is enhanced, but tissue damage may occur

Engineering Contradiction:

Improvesenescent cell elimination capabilityVSAvoidtissue damage from stress

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of endoplasmic reticulum stress into a beneficial therapeutic mechanism. By using 2'-fucosyllactose to induce controlled endoplasmic reticulum stress, the patent activates cellular pathways that lead to senescent cell elimination through autophagy and apoptosis, while the stress level is carefully regulated to prevent excessive tissue damage. The harmful stress is transformed into a selective elimination mechanism.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentEP4670722A1Prophylactic or ameliorating agent for cell aging

Publication Date: 2025.12.31 KYOWA PHARMA CHEM CO LTD

Figure 1
Figure 2
Figure 3

AI summary

A prophylactic or ameliorating agent for cell aging, comprising 2'-fucosyllactose.